Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts ("ADRs") of GSK plc between February 5, ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

London stocks edged higher on Wednesday as investors weighed the ongoing effects of trade tensions linked to US president ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion-pound ...